Project Grant R01CA288836
Award Date
12/13/24
Completion Date
11/30/29
Dollars Obligated
$755K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Bar Harbor, ME 04609, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $547,945 to The Johns Hopkins University to conduct research on the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The key objectives are to: Investigate how biological factors such as prior cardiac injury, age, and sex modulate the risk of immune checkpoint inhibitor-induced myocarditis. Comprehensively characterize the 3D localization and transcriptional...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $684,367 to the Baylor College of Medicine to conduct research aimed at identifying new predictors of response to immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC). The key objectives are to: 1) Identify intratumoral microbiome profiles predictive of ICI response using whole-metagenome sequencing; 2) Characterize spatial immune...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $689,934 to the Dana-Farber Cancer Institute (DFCI) to conduct research on the genetic factors underlying immune-related adverse events (IRAEs) associated with immune checkpoint inhibitor (ICI) cancer treatments. The key objectives are to: 1) Perform the largest genome-wide association study (GWAS) of IRAEs across over 13,000 ICI-treated patients, to identify shared and...
This federal Project Grant award of $176,712 from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research to investigate the role of CD91-mediated signaling in priming T cell responses to nascent, emerging tumors. The primary awardee, the University of Pittsburgh, will develop a new mouse model to test the importance of CD91-mediated signaling in response to tumor-derived heat shock proteins for cancer immunosurveillance. This research aims to advance the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $649,679 to support research by The Institute For Cancer Research aimed at triggering a viral mimicry response in small cell lung cancer (SCLC) to enhance immunotherapy responsiveness. The key objectives are to determine how targeting the DHX9 helicase protein can induce the accumulation of immunogenic double-stranded RNAs and RNA-DNA hybrids in SCLC cells, leading to antiviral...
This $674,996 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Sanford Burnham Prebys Medical Discovery Institute (SBP) to determine if targeting the PSGL-1 checkpoint inhibitor can promote the development and/or maintenance of CD8+ T cells essential for anti-tumor responses to PD-1 immune checkpoint blockade (ICB) therapy. The key objectives are to evaluate if PSGL-1 blockade can generate or sustain tumor-specific...
This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides funding to support the computational research and platform development activities of a laboratory-based research specialist at the Cleveland Clinic Lerner College of Medicine. The key products and services delivered under this $212,567 award, spanning from September 2024 to August 2029, include: Computational analysis of cancer patient-derived next-generation...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $127,629 to the President and Fellows of Harvard College's Harvard T.H. Chan School of Public Health to conduct research on the role of human leukocyte antigen (HLA) variations in cellular immunity and the efficacy of immune checkpoint inhibitor monotherapy for non-small cell lung cancer patients. The key objectives are to: 1) identify the mechanisms linking germline and somatic HLA...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...